Autoimmune disorders associated with myelodysplastic syndromes: clinical, prognostic and therapeutic implications

Fozza, Claudio; Murtas, Andrea; Caocci, Giovanni; Nasa, Giorgio La

doi:10.1016/j.leukres.2022.106856

Cited by 7 publications

(6 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the relationship between AD which based on immune inflammatory response and MDS has also attracted the attention of the scholars. According to relevant researches, AD appears in around one third of MDS patients which was significantly higher than that of healthy people (6), while AD also increased the risk of MDS with an odds ratio (OR) from 1.5 to 3.5 (6,7). The effect of AD on the clinical characteristics and prognosis to MDS patients is still controversial.…”

Section: Mds and Autoimmune Disordersmentioning

confidence: 99%

The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification

Peng

Zhu²,

Di³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Myelodysplastic syndrome (MDS) is a heterogeneous group of myeloid clonal diseases with diverse clinical courses, and immune dysregulation plays an important role in the pathogenesis of MDS. However, immune dysregulation is complex and heterogeneous in the development of MDS. Lower-risk MDS (LR-MDS) is mainly characterized by immune hyperfunction and increased apoptosis, and the immunosuppressive therapy shows a good response. Instead, higher-risk MDS (HR-MDS) is characterized by immune suppression and immune escape, and the immune activation therapy may improve the survival of HR-MDS. Furthermore, the immune dysregulation of some MDS changes dynamically which is characterized by the coexistence and mutual transformation of immune hyperfunction and immune suppression. Taken together, the authors think that the immune dysregulation in MDS with different risk stratification can be summarized by an advanced philosophical thought “Yin-Yang theory” in ancient China, meaning that the opposing forces may actually be interdependent and interconvertible. Clarifying the mechanism of immune dysregulation in MDS with different risk stratification can provide the new basis for diagnosis and clinical treatment. This review focuses on the manifestations and roles of immune dysregulation in the different risk MDS, and summarizes the latest progress of immunotherapy in MDS.

show abstract

Section: Mds and Autoimmune Disordersmentioning

confidence: 99%

The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification

Peng

Zhu²,

Di³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…The relationship between MDS and autoimmune diseases is receiving increasing clinical attention, and MDS, like other malignancies, can present with various paraneoplastic immune phenomena such as vasculitis, arthritis, Sweet syndrome, and immune hemolytic anemia (Grignano et al, 2018;Fozza et al, 2022). Chondrocytes are an important factor in cartilage tissue to Frontiers in Genetics frontiersin.org maintain articular cartilage homeostasis, and studies have confirmed that massive apoptosis of chondrocytes and abnormal expression of immune factors are one of the important causes of OA (Ishii et al, 2022).…”

Section: Discussionmentioning

confidence: 99%

Bioinformatics gene analysis of potential biomarkers and therapeutic targets of osteoarthritis associated myelodysplastic syndrome

Xin

Li²,

Dong³

et al. 2023

Front. Genet.

View full text Add to dashboard Cite

Objective: Osteoarthritis (OA) and Myelodysplastic syndrome (MDS) are diseases caused by the same immune disorder with unclear etiology and many similarities in clinical manifestations; however, the specific mechanisms between osteoarthritis and myelodysplastic syndrome are unclear.Methods: The expression profile microarrays of osteoarthritis and myelodysplastic syndrome were searched in the GEO database, the intersection of their differential genes was taken, Venn diagrams were constructed to find common pathogenic genes, bioinformatics analysis signaling pathway analysis was performed on the obtained genes, and protein-protein interaction networks were constructed to find hub genes in order to establish diagnostic models for each disease and explore the immune infiltration of hub genes.Results: 52 co-pathogenic genes were screened for association with immune regulation, immune response, and inflammation. The mean area under the receiver operating characteristic (ROC) for all 10 genes used for co-causal diagnosis ranged from 0.71–0.81. Immune cell infiltration analysis in the myelodysplastic syndrome subgroup showed that the relative numbers of Macrophages M1, B cells memory, and T cells CD4 memory resting in the myelodysplastic syndrome group were significantly different from the normal group, however, in the osteoarthritis subgroup the relative numbers of Mast cells resting in the osteoarthritis subgroup was significantly different from the normal group.Conclusion: There are common pathogenic genes in osteoarthritis and myelodysplastic syndrome, which in turn mediate differential alterations in related signaling pathways and immune cells, affecting the high prevalence of osteoarthritis and myelodysplastic syndrome and the two disease phenomena.

show abstract

“…Autoimmune disorders (ADs) typically impact around 3 to 10% of the world's population and can occasionally lead to morbidity and mortality incidences comparable to those seen in cancer and cardiac illnesses [3,4]. Furthermore, AD and MDS can occur concomitantly, with research reporting that about 10-30% of MDS patients develop ADs [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Effects of Autoimmune Disorders on Myelodysplastic Syndrome Outcomes: A Systematic Review

Saowapa,

Polpichai,

Tanariyakul

et al. 2024

Hemato

View full text Add to dashboard Cite

Background: Autoimmune disorders (ADs) are prevalent among patients with myelodysplastic syndrome (MDS), yet their impact on MDS outcomes, including overall survival (OS), mortality, and transformation to acute myeloid leukemia (AML), is not well defined. Methods: We conducted a systematic review of articles published up to April 2024, sourced from PubMed, Web of Science, Embase, and Google Scholar, focusing on the influence of ADs on survival and AML transformation rates in MDS patients. The methodological quality of each study was assessed using the Newcastle Ottawa Scale. Results: From 8 studies that met the inclusion criteria, ADs were present in 17.5% (3074/17,481) of MDS patients. Data analysis indicated mortality rates ranging from 15.3% to 67% in MDS patients with ADs and 12% to 69% in those without. The rate of AML transformation varied from 0% to 23% in patients with ADs compared to 4% to 30% in those without. Conclusions: The influence of ADs on survival and AML transformation in MDS patients appears variable. This systematic review highlights the need for further large-scale prospective studies to clarify the relationship between ADs and MDS outcomes.

show abstract

Autoimmune disorders associated with myelodysplastic syndromes: clinical, prognostic and therapeutic implications

Cited by 7 publications

References 100 publications

The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification

The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification

Bioinformatics gene analysis of potential biomarkers and therapeutic targets of osteoarthritis associated myelodysplastic syndrome

Effects of Autoimmune Disorders on Myelodysplastic Syndrome Outcomes: A Systematic Review

Contact Info

Product

Resources

About